Clinical trial
A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
NCT07128693 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- September 30, 2025
- Completion date
- December 31, 2028
- Enrollment
- 60 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.